Viewing Study NCT01497093

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:12 AM
Ignite Modification Date: 2026-02-01 @ 5:46 AM
Study NCT ID: NCT01497093
Status: COMPLETED
Last Update Posted: 2020-04-07
First Post: 2011-12-20
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Sponsor: Celgene
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Myeloma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Myeloma View
None Multiple Myeloma View
None Relapsed Multiple Myeloma View
None Relapsed and Refractory Multiple Myeloma View
None Refractory Myeloma View
None Resistant Multiple Myeloma View
None Treatment-resistant Multiple Myeloma View
None Pomalidomide View
None Lenalidomide-resistant View